# BLA for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients with Disorders Affecting the Hematopoietic System:  Guidance for Industry - FDA Guidance Document

Source: https://www.keypedia.com/guidances/guidance-document/bla-for-minimally-manipulated-unrelated-allogeneic-placentalumbilical-cord-blood-intended-for-hematopoietic-and-immunologic-reconstitution-in-patients-with-disorders-affecting-the-hematopoietic-system-guidance-for-industry/92eb43cc-c22d-4b90-b9cb-77d1adfe8331

> FDA guidance document: BLA for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients with Disorders Affecting the Hematopoietic System:  Guidance for Industry. Issue date: March 01, 2014. Get complete insights and analysis.

---

## Details

- Title: BLA for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients with Disorders Affecting the Hematopoietic System:  Guidance for Industry
- Communication Type: Guidance Document
- Product Type: biologics
- Office Name: Center for Biologics Evaluation and Research
- Office URL: /offices/center-for-biologics-evaluation-and-research/dd9e8ea7-6f04-4ed1-b0d7-e7e6b264570d
- Issue Date: 2014-03-01
- Last Changed: 2019-05-16
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2006-D-0157">FDA-2006-D-0157</a>

## Related Documents

- [IND Applications for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients with Disorders Affecting the Hematopoietic System:  Guidance for Industry and FDA Staff](https://www.keypedia.com/guidances/guidance-document/ind-applications-for-minimally-manipulated-unrelated-allogeneic-placentalumbilical-cord-blood-intended-for-hematopoietic-and-immunologic-reconstitution-in-patients-with-disorders-affecting-the-hematopoietic-system-guidance-for-industry-and-fda-staff/11261772-181c-4193-9a2c-ff10ff47b76a)
- [Clinical Considerations for Therapeutic Cancer Vaccines:  Guidance for Industry](https://www.keypedia.com/guidances/guidance-document/clinical-considerations-for-therapeutic-cancer-vaccines-guidance-for-industry/e0e6e4e0-a883-4f71-bf37-784e147d32d9)
- [Blood Establishment Computer System Validation in the User's Facility:  Guidance for Industry](https://www.keypedia.com/guidances/guidance-document/blood-establishment-computer-system-validation-in-the-users-facility-guidance-for-industry/0d458283-d7d4-4dbf-b665-009d53641a92)